Correlation Between Cue Biopharma and Apellis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Cue Biopharma and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cue Biopharma and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cue Biopharma and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Cue Biopharma and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cue Biopharma with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cue Biopharma and Apellis Pharmaceuticals.

Diversification Opportunities for Cue Biopharma and Apellis Pharmaceuticals

0.63

Correlation Coefficient

Cue Biopharma  Apellis Pharmaceuticals

Poor diversification

The 3 months correlation between Cue and Apellis is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Cue Biopharma and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Cue Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cue Biopharma are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Cue Biopharma i.e., Cue Biopharma and Apellis Pharmaceuticals go up and down completely randomly.

Pair Corralation between Cue Biopharma and Apellis Pharmaceuticals

Considering the 90-day investment horizon Cue Biopharma is expected to generate 2.14 times more return on investment than Apellis Pharmaceuticals. However, Cue Biopharma is 2.14 times more volatile than Apellis Pharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. Apellis Pharmaceuticals is currently generating about -0.13 per unit of risk. If you would invest  104.00  in Cue Biopharma on December 27, 2024 and sell it today you would lose (3.50) from holding Cue Biopharma or give up 3.37% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Cue Biopharma  vs.  Apellis Pharmaceuticals

Cue Biopharma

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Cue Biopharma may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Apellis Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Cue Biopharma and Apellis Pharmaceuticals

The main advantage of trading using opposite Cue Biopharma and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cue Biopharma position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.

The idea behind Cue Biopharma and Apellis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.